- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma
June 13th 2025, 4:30pm
European Hematology Association Congress
Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.
Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo
June 12th 2025, 9:04pm
European Hematology Association Congress
Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML
June 12th 2025, 9:00pm
European Hematology Association Congress
Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.
Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL
June 12th 2025, 4:16pm
European Hematology Association Congress
Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.
Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma
June 11th 2025, 8:00pm
Sylvester Comprehensive Cancer Center, University of Miami
Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.
EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer
June 10th 2025, 7:52pm
First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.
Elacestrant Displays Potential as Combination Backbone in ER+ Breast Cancer After CDK4/6 Inhibition
June 10th 2025, 12:00pm
Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.
UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC
June 9th 2025, 8:00pm
UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.
RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC
June 8th 2025, 12:00pm
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.
Padeliporfin VTP Shows Safety, Clinical Activity in Upper Tract Urothelial Cancer
June 7th 2025, 10:00am
The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.
Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC
June 6th 2025, 8:00pm
Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.
Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress
June 6th 2025, 1:00pm
European Hematology Association Congress
Experts highlight key abstracts to watch for at the 2025 EHA Congress.
RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma
June 6th 2025, 12:00pm
RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.
Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL
June 5th 2025, 4:30pm
Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.
Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC
June 5th 2025, 2:43pm
The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.
Highlighting the Key Takeaways From ASH 2024
June 5th 2025, 12:10pm
Unpacking Key Data from ASH 2024
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy, bispecifics, and minimal residual disease (MRD) monitoring are reshaping lymphoma treatment strategies, with emerging data showing promising outcomes for various lymphoma subtypes and ongoing trials exploring optimal sequencing of these therapies.
Treatment and Management of MM with Amyloidosis
June 5th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 are shaping the treatment and management of multiple myeloma (MM) with amyloidosis, emphasizing early diagnosis, novel therapies, and personalized treatment strategies to improve patient outcomes.
Recommendations For Future Clinical Trials in R/R MM
June 5th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).
Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma
June 4th 2025, 9:05pm
JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.
Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy
June 4th 2025, 7:25pm
Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.